Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Best overall response</td><td class="align_center">A single agent (<i>n</i> = 38), no. (%)</td><td class="align_center">Combination therapy (<i>n</i> = 37), no. (%)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Complete response</td><td class="align_center">0 (0)</td><td class="align_center">3 (8)</td></tr><tr><td class="align_left">Partial response</td><td class="align_center">4 (11)</td><td class="align_center">8 (22)</td></tr><tr><td class="align_left">Overall response</td><td class="align_center">4 (11)</td><td class="align_center">11 (30)</td></tr><tr><td class="align_left">Stable disease</td><td class="align_center">19 (50)</td><td class="align_center">12 (32)</td></tr><tr><td class="align_left">Progressive disease</td><td class="align_center">14 (37)</td><td class="align_center">13 (35)</td></tr><tr><td class="align_left">Not evaluable or not assessed</td><td class="align_center">1 (3)</td><td class="align_center">1 (3)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Overall response rate for doxorubicin monotherapy and combination therapy.</div>

Sarcoma

tab4

Table 4

Table 4: Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution 

Table 4 | Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution 